Jesper F Lau

This inventor holds 99 USPTO granted patents and 38 published patent applications, plus 3 CIPO patents and 34 EPO patents, primarily in GLP-1 Derivatives (CPC class C07K14-605). Top assignees: Novo Nordisk A/s, Transtech Pharma, Inc., British Technology Group Intercorporate Licensing Limited. Active years: 1994-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jesper F Lau. Retrieved from https://idiyas.com/inventor/jesper-f-lau

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 99 (Patent Applications = 38)

% Patents Active = 67.7

CIPO Patents = 3 (Patent Applications = 26)

EPO Patents = 34 (Patent Applications = 40)

Average Co-Inventor Count = 4.8

ph-index = 18

Forward Citations = 1,251(Granted Patents)

Forward Citations (Not Self Cited) = 1,169(Dec 10, 2025)

Inventors with similar research interests:

🔬 See more inventors

Company Filing History:

Transtech Pharma, Inc.

patents

1 out of 6

British Technology Group Intercorporate Licensing Limited

7. 1 out of 834,513

Other

patents

Years Active: 1994-2026

Loading Chart...

Areas of Expertise:

GLP-1 Compounds

Glucagon Analogues

Amylin Receptor Agonists

Obesity Treatment

GIP Derivatives

Double-Acylated GLP-1

Stable GLP-1

Protracted Exendin-4

CGRP Derivatives

Heteroaryl-Ureas

Biaryl Phosphodiesterase Inhibitors

Acylated Exendin-4

99 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12616739 - GLP-1 PRODRUGS AND USES THEREOF (2026-05-05),

2. 12116388 - Amylin receptor agonists (2024-10-15),

3. 11753455 - Compounds for treatment of obesity (2023-09-12),

4. 11633459 - GIP derivatives and uses thereof (2023-04-25),

5. 11518795 - Double-acylated GLP-1 derivatives (2022-12-06),

6. 10822385 - EGF(A) analogues with fatty acid substituents (2020-11-03),

7. 10689429 - Double-acylated GLP-1 compounds (2020-06-23),

8. 10604555 - GIP derivatives and uses thereof (2020-03-31),

9. 10604554 - Double-acylated GLP-1 derivatives (2020-03-31),

10. 10570184 - GLP-1/glucagon receptor co-agonists for medical use (2020-02-25),

11. 10308700 - GLP-1 derivatives (2019-06-04),

12. 10000542 - Double-acylated GLP-1 derivatives (2018-06-19),

13. 9988430 - Stable GLP-1 based GLP-1/glucagon receptor co-agonists (2018-06-05),

14. 9963496 - Stable glucagon analogues and use for treatment of hypoglycaemia (2018-05-08),

15. 9920106 - GLP-1 compounds (2018-03-20),

Title: Innovator Spotlight: Jesper F Lau

Introduction:

Jesper F Lau, a prolific inventor based in Farum, Denmark, has made significant contributions to the field of medical innovation with an impressive portfolio of 97 patents. His groundbreaking work focuses on developing compounds for the treatment of obesity, demonstrating a deep understanding of the complex mechanisms behind weight regulation.

Latest Patents:

One of Jesper F Lau's latest patents involves the creation of compounds designed to target specific areas in the brain that play a crucial role in the regulation of body weight. These compounds incorporate an allosteric ligand to a receptor located in the blood-brain barrier, paving the way for new treatments aimed at addressing overweight and obesity. By utilizing GLP-1 receptor agonists and targeting receptors like the transferrin receptor, Jesper's inventions demonstrate promising results in reducing food intake and promoting weight loss, as confirmed by in vivo studies in mice.

Additionally, Jesper F Lau has patented derivatives of glucose-dependent insulinotropic polypeptide (GIP) analogues that boast improved physical stability and prolonged action profiles. These novel peptides act as agonists at the GIP receptor, offering potential benefits for weight management and the treatment of conditions such as obesity, diabetes, and non-alcoholic steatohepatitis (NASH).

Career Highlights:

Having worked with renowned companies like Novo Nordisk A/S and Transtech Pharma, Inc., Jesper F Lau has honed his expertise in the intersection of science and pharmaceutical development. His innovative approach to medical research has led to the creation of cutting-edge solutions that address critical health challenges, showcasing his commitment to driving progress in the field.

Collaborations:

Throughout his career, Jesper F Lau has collaborated with esteemed professionals such as Anthony Murray and Thomas Kruse Hansen, leveraging their collective insights and expertise to push the boundaries of medical innovation. These collaborations have not only enriched his own work but have also contributed to a collaborative culture of discovery and advancement in the industry.

Conclusion:

In conclusion, Jesper F Lau stands out as a visionary inventor who continues to make significant strides in the realm of medical innovation. His pioneering work in developing compounds for the treatment of obesity and related conditions underscores his dedication to improving the quality of life for individuals worldwide. With a remarkable portfolio of patents and a history of successful collaborations, Jesper F Lau remains a leading figure in the field, shaping the future of healthcare through his inventive creations.

Profile summary based on public USPTO records.